Refraction following PRK stable over eight years

Article

Postoperative refraction following photorefractive keratectomy (PRK) remains stable from the second year postoperatively through to eight years.

Postoperative refraction following photorefractive keratectomy (PRK) remains stable from the second year postoperatively through to eight years, according to Hossein Mohammad Rabei and colleagues from the Basir Eye Center, Tehran, Iran.

The researchers obtained data from 2,141 myopic patients who underwent PRK with single-step method using a NIDEK EC-5000 excimer laser with 5-6 mm ablation zones in Basir Eye Center, Tehran during 1994-1996.

A total of 179 myopic eyes of 98 patients who had undergone PRK and completed eight years follow-up were included in the study. Follow-up examinations were performed one, three, six and 12 months and two and eight years after surgery. The treated eyes were divided into three groups according to preoperative refraction: low myopes, medium myopes and high myopes.

After eight years follow-up, the percentage of eyes within ±1 D of emmetropia was 69.1%, 30% and 46.2% in the low, medium and high groups, respectively. Changes in myopic regression stabilized in all myopic groups within two years and was significantly correlated to preoperative spherical equivalent refraction. Corneal haze was recorded in 5% but cleared within two years in 89% of cases.

The results of this long-term study demonstrate that refraction following PRK does remain stable for up to eight years following surgery.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.